Valneva (VALN) Competitors

Vir Biotechnology (NASDAQ:VIR) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Is VIR or VALN more profitable?

Valneva has a net margin of -4.35% compared to Vir Biotechnology's net margin of -678.40%. Valneva's return on equity of -3.93% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Valneva	-4.35%	-3.93%	-1.42%

Does the MarketBeat Community prefer VIR or VALN?

Vir Biotechnology received 19 more outperform votes than Valneva when rated by MarketBeat users. However, 61.82% of users gave Valneva an outperform vote while only 54.64% of users gave Vir Biotechnology an outperform vote.

Company	Underperform	Outperform
Vir Biotechnology	Outperform Votes 53 54.64%	Underperform Votes 44 45.36%
Valneva	Outperform Votes 34 61.82%	Underperform Votes 21 38.18%

Do analysts prefer VIR or VALN?

Vir Biotechnology currently has a consensus price target of $34.83, indicating a potential upside of 234.94%. Valneva has a consensus price target of $17.50, indicating a potential upside of 202.77%. Given Vir Biotechnology's higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Valneva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, VIR or VALN?

Valneva has higher revenue and earnings than Vir Biotechnology. Valneva is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$86.18M	16.62	-$615.06M	-$3.92	-2.65
Valneva	$165.52M	2.84	-$109.78M	-$0.13	-44.46

Does the media refer more to VIR or VALN?

In the previous week, Valneva had 8 more articles in the media than Vir Biotechnology. MarketBeat recorded 13 mentions for Valneva and 5 mentions for Vir Biotechnology. Valneva's average media sentiment score of 0.48 beat Vir Biotechnology's score of 0.29 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, VIR or VALN?

Vir Biotechnology has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in VIR or VALN?

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Valneva beats Vir Biotechnology on 11 of the 18 factors compared between the two stocks.